Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 5/20 | 0.56 |
| ▸ | WNT3A | P56704 | 4/20 | 0.56 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21231294 | 1.00 | CTNNB1 (0.56) | CTNNB1WNT3AKMOTSHRSMN1; SMN2 | |
| SCHEMBL20032579 | 0.88 | CTNNB1 (0.52) | CTNNB1WNT3AKMOTSHRSMN1; SMN2 | |
| SCHEMBL15319218 | 0.80 | KMO (0.56) | CTNNB1KMOTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL23024775 | 0.80 | CTNNB1 (0.68) | CTNNB1WNT3ATSHRALDH1A1TDP1 | |
| SCHEMBL31396077 | 0.80 | CTNNB1 (0.68) | CTNNB1WNT3ATSHRALDH1A1TDP1 | |
| SCHEMBL15337102 | 0.77 | KMO (0.52) | CTNNB1WNT3AKMOTSHRNPC1 | |
| SCHEMBL16614190 | 0.75 | CTNNB1 (0.55) | CTNNB1WNT3AKMOALDH1A1NPC1 | |
| SCHEMBL21231721 | 0.75 | ALDH1A1 (0.60) | CTNNB1WNT3AKMOSMN1; SMN2ALDH1A1 | |
| SCHEMBL15337040 | 0.75 | ALDH1A1 (0.60) | CTNNB1WNT3AKMOSMN1; SMN2ALDH1A1 | |
| SCHEMBL21382764 | 0.72 | CTNNB1 (0.58) | CTNNB1WNT3ATSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272611-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-22 | — | — | US | claimed |
| EP-3049389-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3049389-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190047977-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20190047977-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2019-02-14 | — | — | US | disclosed |
| US-9938252-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938252-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938252-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160272611-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160272611-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160272611-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-22 | — | — | US | disclosed |
| WO-2015047978-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272611-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, AADAT | CTNNB1 4177/4885WNT3A 1977/4885KMO 1/4885 |
| US-20190047977-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, AADAT | CTNNB1 4164/4885WNT3A 1966/4885KMO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.